Other formats:
BibTeX
LaTeX
RIS
@proceedings{2247554, author = {De Vlam, Kurt and Taylor, Peter and Mease, Philip J. and Peloso, Paul and Wetzel, Dieter and Brun, Nicolai and Wiens, Brian and BrandtandJuergens, Jan and Drescher, Edit and Dokoupilová, Eva and RowinskaandOsuch, Anna and Martin, Nadia AbdelandKader and Behrens, Frank}, keywords = {izokibep; enthesitis; dactylitis; nail outcomes; clinical trial}, language = {eng}, title = {Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial}, year = {2022} }
TY - CONF ID - 2247554 AU - De Vlam, Kurt - Taylor, Peter - Mease, Philip J. - Peloso, Paul - Wetzel, Dieter - Brun, Nicolai - Wiens, Brian - Brandt-Juergens, Jan - Drescher, Edit - Dokoupilová, Eva - Rowinska-Osuch, Anna - Martin, Nadia Abdel-Kader - Behrens, Frank PY - 2022 TI - Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial KW - izokibep KW - enthesitis KW - dactylitis KW - nail outcomes KW - clinical trial N2 - PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement. Unresolved enthesitis leads to chronic pain and reduced quality of life1. IL-17 inhibitors have demonstrated benefits across multiple disease features. Izokibep is a unique IL-17A inhibitor with high potency (0.3 pM), small size (18.6 kD) and half-life extending albumin binding. The purpose is to assess the efficacy of izokibep 40 mg Q2W and 80 mg Q2W versus placebo on measures of enthesitis (most common being Leeds Enthesitis Index (LEI), as well as SPARCC), dactylitis and nails, and explore how these disease features impact quality of life (PsAID questionnaire) over 16 weeks. Drug safety was evaluated. ER -
DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Frank BEHRENS. \textit{Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial}. 2022. ISSN~2326-5191.
|